Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

IMPORTANCE: Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. OBJECTIVE: To determine if pembrolizumab plus neoadjuvant chemotherapy (NACT) in early-stage breast canc...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Nanda, Rita, Liu, Minetta C., Yau, Christina, Shatsky, Rebecca, Pusztai, Lajos, Wallace, Anne, Chien, A. Jo, Forero-Torres, Andres, Ellis, Erin, Han, Heather, Clark, Amy, Albain, Kathy, Boughey, Judy C., Jaskowiak, Nora T., Elias, Anthony, Isaacs, Claudine, Kemmer, Kathleen, Helsten, Teresa, Majure, Melanie, Stringer-Reasor, Erica, Parker, Catherine, Lee, Marie C., Haddad, Tufia, Cohen, Ronald N., Asare, Smita, Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Steeg, Katherine, Asare, Adam, Matthews, Jeffrey B., Berry, Scott, Sanil, Ashish, Schwab, Richard, Symmans, W. Fraser, van ‘t Veer, Laura, Yee, Douglas, DeMichele, Angela, Hylton, Nola M., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Berry, Donald A., Esserman, Laura J.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2020
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7058271/
https://ncbi.nlm.nih.gov/pubmed/32053137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6650
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares